The lawsuit, spearheaded by the Rosen Law Firm, accuses Erasca executives of violating federal securities laws by issuing false or misleading statements concerning the company's experimental therapy. According to the complaint, the firm repeatedly marketed ERAS-0015 as a superior, "best-in-class" drug, citing preclinical results that allegedly compared favorably to Revolution Medicines' competing candidate, RMC-6236.

Plaintiffs argue these comparisons lacked a reasonable basis and failed to disclose that the methodology was improper. The filing further suggests the company ignored significant risks, including potential patent and trade secret disputes. Investors who acquired shares during the designated period may be eligible for compensation through a contingency fee arrangement. While no class has been certified yet, those interested in participating or seeking lead status can contact attorney Phillip Kim before the court-imposed cutoff.